Ianalumab (VAY736): A Comprehensive Analysis of a Dual-Action, BAFF-Receptor-Targeting Monoclonal Antibody for Autoimmune Disease

Executive Summary

Ianalumab (VAY736) is an investigational, fully human IgG1κ monoclonal antibody representing a next-generation approach to B-cell modulation for the treatment of autoimmune diseases. Developed by Novartis, it is distinguished by a rationally designed dual mechanism of action that targets the B-cell activating factor receptor (BAFF-R). This mechanism combines the competitive blockade of BAFF-R-mediated survival signaling with potent, direct B-cell depletion via enhanced antibody-dependent cellular cytotoxicity (ADCC), a feature engineered through afucosylation of the antibody's Fc region. This dual action is hypothesized to produce a deeper and more durable B-cell suppression than preceding therapies, addressing the limitations of both B-cell depleting agents and BAFF-pathway inhibitors.

The extensive clinical development program for Ianalumab has demonstrated a compelling efficacy and safety profile across several B-cell-mediated autoimmune disorders. In primary Sjögren's Syndrome, a condition with no approved systemic disease-modifying therapies, Ianalumab is the first agent in a large, randomized trial to meet its primary endpoint, showing a significant dose-dependent improvement in disease activity. In Systemic Lupus Erythematosus (SLE), Phase 2 data demonstrated superiority over placebo on a clinically meaningful composite endpoint of disease activity reduction coupled with corticosteroid tapering, supporting its advancement into a global Phase 3 program. Furthermore, in hematologic autoimmune diseases, Ianalumab has shown promising activity, inducing rapid and confirmed responses in heavily pretreated patients with Primary Immune Thrombocytopenia (ITP) and is being investigated as a potential durable, treatment-free remission-inducing therapy in both ITP and Warm Autoimmune Hemolytic Anemia (wAIHA).

The safety profile of Ianalumab across multiple studies appears favorable and manageable, characterized primarily by mild-to-moderate injection-site reactions and a low incidence of serious infections, which could represent a significant advantage over other potent immunosuppressants. Supported by a robust clinical data package and a clear strategic development path, including Orphan Drug Designation for ITP from the U.S. FDA and agreed-upon Paediatric Investigation Plans with the European Medicines Agency, Ianalumab is positioned as a high-potential, late-stage asset poised to address significant unmet medical needs across a spectrum of challenging autoimmune conditions.

Section 1: Profile of an Investigational Immunomodulator

This section establishes the foundational identity of Ianalumab, providing the necessary identifiers and context for the detailed analysis that follows.

1.1. Identification and Core Properties

Ianalumab is a biologic entity under clinical investigation, identified by a standardized set of names and registry numbers that ensure its precise tracking across scientific literature, clinical trial databases, and regulatory filings.

• Generic Name: The officially assigned International Nonproprietary Name (INN) for this molecule is Ianalumab.[1]
• Development Codes & Synonyms: Throughout its development by Novartis, the compound has been primarily referred to by the internal code VAY736.[1] Variations of this code, such as VAY-736 and VAY 736, are also used interchangeably.[2] Additional synonyms found in technical literature include anti-TNFRSF13C/BAFFR/CD268 antibody, reflecting its molecular target, and NOV-5.[4]
• Registry Identifiers: Ianalumab is cataloged in major biomedical databases under the following unique identifiers:
• DrugBank ID: DB16666 [2]
• CAS Number: 1929549-92-7 [1]
• UNII (Unique Ingredient Identifier): ZN2GQ3II96 [1]
• KEGG (Kyoto Encyclopedia of Genes and Genomes): D12151 [1]
• Drug Class & Modality: Ianalumab is classified as a biotech drug, specifically falling under the categories of Protein-Based Therapies and Monoclonal Antibodies (mAbs).[2] It is a fully human monoclonal antibody of the immunoglobulin G1 kappa (IgG1κ) isotype.[4]
• Physical/Chemical Properties: For research and formulation purposes, Ianalumab is described as a colorless to light yellow liquid.[4] Its molecular weight is reported to be approximately 145.5 kDa to 146.44 kDa.[3] A research-grade formulation is specified as 100 mM Pro-Ac, 20mM Arg, at a pH of 5.0.[5]

1.2. Developmental Lineage

The origin and development of a monoclonal antibody are critical to understanding its properties, particularly its potential for immunogenicity.

• Originator & Developer: Ianalumab is being developed by Novartis Pharmaceuticals.[1] Its genesis, however, traces back to a collaboration with MorphoSys AG.[6] The antibody was derived from the MorphoSys fully human combinatorial antibody library (HuCAL) technology platform.[5] This technological origin is significant, as it clarifies that Ianalumab is a "fully human" antibody, rather than a "humanized" one—a term occasionally used in some commercial literature.[3] Fully human antibodies are generated in vitro using human gene libraries and are designed to minimize the potential for an immune response in patients compared to chimeric or humanized antibodies, which contain non-human protein sequences. Further molecular analysis suggests that Ianalumab may be identical to the molecule designated mAb MORO7347 in a Novartis patent, providing a clear link in its intellectual property lineage.[9]

The comprehensive and consistent documentation of Ianalumab, from its origin in the HuCAL platform to its progression as VAY736 within the Novartis pipeline, signifies a mature and well-characterized biopharmaceutical asset.

Table 1: Key Identifiers and Properties of Ianalumab

Property	Value	Source(s)
Generic Name	Ianalumab	1
Development Code	VAY736	1
DrugBank ID	DB16666	2
CAS Number	1929549-92-7	1
UNII	ZN2GQ3II96	1
Class	Biotech, Protein-Based Therapy, Monoclonal Antibody	2
Sub-Class	Fully Human IgG1κ	4
Molecular Weight	~145.5 kDa	5
Developer	Novartis	1
Origin Technology	MorphoSys HuCAL Platform	5

Section 2: A Differentiated Mechanism of Action: Dual B-Cell Suppression

The therapeutic rationale for Ianalumab is rooted in its sophisticated and differentiated dual mechanism of action, which targets B-lymphocytes through two distinct but synergistic pathways. This design represents a rationally evolved approach to B-cell modulation, intended to overcome the known limitations of earlier-generation therapies.

2.1. The B-Cell Activating Factor (BAFF) Pathway in Autoimmunity

B-cells are central players in the pathogenesis of numerous autoimmune diseases, including Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome.[12] Their pathogenic role is multifaceted, involving the production of autoantibodies, presentation of autoantigens to T-cells, and secretion of pro-inflammatory cytokines. The survival, maturation, and activation of B-cells are critically dependent on a cytokine known as B-cell activating factor (BAFF), which is also referred to as B-lymphocyte stimulator (BLyS).[14]

In a healthy immune system, BAFF levels are tightly regulated to maintain B-cell homeostasis. However, in many autoimmune conditions, BAFF levels are pathologically elevated.[12] This overabundance of BAFF provides potent survival signals that rescue autoreactive B-cells from programmed cell death (apoptosis), allowing them to proliferate and differentiate into autoantibody-secreting plasma cells. These autoantibodies subsequently form immune complexes, deposit in tissues, and drive the inflammation and organ damage characteristic of these diseases.[15] Consequently, the BAFF pathway has become a prime therapeutic target for the treatment of systemic autoimmune disorders.

2.2. Component 1: Blockade of BAFF Receptor (BAFF-R) Signaling

The first component of Ianalumab's mechanism involves the direct and competitive inhibition of BAFF signaling at the B-cell surface. Ianalumab is a high-affinity monoclonal antibody that specifically targets the B-cell-activating factor receptor (BAFF-R), a protein also known as Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C) or CD268.[1] BAFF-R is the principal receptor for BAFF and is expressed predominantly on B-cells.

By binding directly to BAFF-R, Ianalumab physically obstructs the interaction between the BAFF ligand and its receptor.[7] This action effectively cuts off the downstream survival signals that BAFF provides to the B-cell.

In vitro studies have confirmed the functional consequences of this blockade, demonstrating that Ianalumab effectively inhibits critical BAFF-induced cellular processes, including the cleavage of Nuclear Factor Kappa B Subunit 2 (NF-κB2), a key step in the signaling cascade, as well as B-cell proliferation and the production of IgG.[12] This blockade of BAFF-R-mediated signaling antagonizes the anti-apoptotic protection conferred by BAFF, thereby promoting the elimination of B-cells that are dependent on this pathway for survival.[3]

This receptor-targeting strategy is a deliberate and important point of differentiation. Other therapies, such as the approved drug belimumab, target the soluble BAFF ligand itself, effectively sequestering it in circulation.[9] By targeting the receptor directly on the B-cell, Ianalumab focuses its activity at the site of signal transduction and, critically, anchors the antibody to the cell surface, which is a prerequisite for its second mechanistic component.

2.3. Component 2: Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC)

The second, and equally important, component of Ianalumab's mechanism is its ability to actively and potently destroy B-cells. This is achieved through a process known as antibody-dependent cellular cytotoxicity (ADCC). Ianalumab has been specifically engineered to maximize this function through a process called glycoengineering, specifically, the removal of fucose sugar residues from the carbohydrate structures on its Fc (fragment, crystallizable) region.[9] This modification, known as afucosylation, significantly increases the antibody's binding affinity for the FcγRIIIa receptor, which is expressed on the surface of immune effector cells, most notably Natural Killer (NK) cells.[12]

The process unfolds as follows:

1. Ianalumab binds to BAFF-R on the surface of a target B-cell.
2. The afucosylated Fc region of the bound Ianalumab then acts as a high-affinity beacon for an NK cell.
3. The NK cell engages the Fc region via its FcγRIIIa receptor, triggering an activation cascade within the NK cell through its immune receptor tyrosine activation motif (ITAM).[3]
4. This activation leads to the NK cell releasing cytotoxic granules (containing perforin and granzymes) that induce apoptosis in the targeted B-cell, resulting in its direct elimination.

This engineered enhancement of ADCC leads to a potent and direct B-cell depleting effect, which complements the passive B-cell suppression achieved through BAFF-R signaling blockade.[4] The combination of these two distinct actions constitutes Ianalumab's novel, dual mechanism of action.[4]

2.4. Comparative Mechanistic Analysis

The dual mechanism of Ianalumab was rationally designed to address the observed limitations of first-generation B-cell targeting therapies, positioning it as a potentially more effective therapeutic agent.

A comparison with its predecessors illustrates its strategic advantages. Rituximab, an anti-CD20 monoclonal antibody, induces profound B-cell depletion. However, this depletion can lead to a compensatory surge in circulating BAFF levels. This elevated BAFF may then provide a potent survival stimulus for any remaining or newly emerging pathogenic B-cell clones, potentially contributing to incomplete responses or subsequent disease flares.[12] Ianalumab's mechanism is designed to mitigate this issue directly: while it potently depletes B-cells via ADCC, its concurrent blockade of BAFF-R ensures that any surviving B-cells are simultaneously starved of this critical survival signal.

Conversely, therapies like belimumab, which neutralize the BAFF ligand, do not directly deplete B-cells. Their effect is more gradual, relying on the natural turnover of B-cells in the absence of survival signals. This can result in a slower onset of action and less profound B-cell suppression compared to what is achievable with a direct depleting agent. Ianalumab integrates both approaches—direct, active depletion and blockade of survival signals—into a single molecule.

This "belt and suspenders" strategy is hypothesized to result in a deeper, more rapid, and more sustained B-cell depletion and, consequently, a more robust and durable clinical response than could be achieved with either mechanism alone. Furthermore, because BAFF-R is not expressed on pro-B and pre-B cell precursors, Ianalumab's action is focused on more mature B-cell populations, potentially sparing the earliest stages of B-cell development in the bone marrow.[9]

Table 2: Mechanistic Comparison of Ianalumab and Other B-Cell Modulating Biologics

Feature	Ianalumab	Rituximab (Anti-CD20)	Belimumab (Anti-BAFF Ligand)
Target	BAFF Receptor (BAFF-R/TNFRSF13C) on B-cells	CD20 on B-cells	Soluble BAFF Ligand (BLyS)
Primary Action	Direct B-cell depletion via ADCC	Direct B-cell depletion via CDC/ADCC	Neutralization of BAFF survival signal
Secondary Action	Blockade of BAFF-R signaling	None	None
Engineering for Potency	Afucosylated Fc region for enhanced ADCC	Chimeric antibody	Fully human antibody
Effect on BAFF Signaling	Direct blockade at the receptor	Indirect; can lead to increased circulating BAFF	Direct neutralization of the ligand
Effect on B-Cell Subsets	Depletes mature B-cells, plasmablasts; spares pro-/pre-B cells	Depletes most B-cell stages except pro-B cells and plasma cells	Reduces survival of mature B-cells and plasmablasts

Section 3: Pharmacological Profile: From Cellular Effects to Systemic Exposure

The pharmacological profile of Ianalumab bridges its molecular mechanism to its clinical effects, encompassing its biological impact on the immune system (pharmacodynamics) and its behavior within the human body (pharmacokinetics).

3.1. Pharmacodynamics (PD)

Pharmacodynamic studies confirm that Ianalumab's dual mechanism translates into profound and measurable biological effects that align with its therapeutic hypothesis.

• B-Cell Depletion: A consistent and cardinal finding across clinical trials is that Ianalumab treatment induces a rapid, profound, and sustained depletion of circulating B-lymphocytes.[17] Flow cytometry analysis demonstrates a statistically significant reduction of total CD19+ B-cell counts. This effect is comprehensive, affecting key B-cell subsets including transitional, naïve, and memory B-cells, as well as the antibody-producing plasmablasts and plasma cells.[19] This cellular-level finding is corroborated at the molecular level by whole blood transcriptome analyses, which show a profound reduction in B-cell-related gene expression, correlating directly with the observed decrease in B-cell numbers.[19]
• Autoantibody Reduction: As a direct consequence of depleting the B-cell lineage, Ianalumab treatment leads to a significant reduction in the levels of pathogenic autoantibodies. In patients with SLE, reductions in titers of anti-double-stranded DNA (anti-dsDNA), anti-C1q, and a panel of anti-extractable nuclear antigens (ENAs), such as anti-U1RNP, have been observed. This effect typically becomes apparent from week 12 of treatment and has been shown to persist for an extended period, through week 68 in some cohorts.[19]
• Biomarker Modulation: The pharmacodynamic effects of Ianalumab extend beyond the B-cell compartment and appear to correlate with clinical response. In the Phase 2 SLE trial, patients who achieved a clinical response (defined as a composite of SRI-4 response and corticosteroid tapering) also demonstrated a decrease in the interferon gene signature (IFNGS) over time.[19] The IFNGS is a well-established biomarker of disease activity in a subset of SLE patients. This finding provides a compelling link between the drug's biological activity and a clinically meaningful outcome, and it suggests a potential biomarker for predicting or monitoring therapeutic response.
• Tissue-Level Effects: The ability of a therapeutic to penetrate and act within target tissues is crucial for efficacy. Preclinical studies in the non-obese diabetic (NOD) mouse model of Sjögren's Syndrome demonstrated that Ianalumab was able to reduce B-cell populations not only in the blood and lymphoid organs but also within the inflamed salivary glands.[12] This provides a strong rationale for its efficacy in organ-specific manifestations of autoimmune disease.

3.2. Pharmacokinetics (PK) and Immunogenicity

While detailed Absorption, Distribution, Metabolism, and Excretion (ADME) data for Ianalumab are not publicly available, as is typical for a monoclonal antibody still in development, the clinical program includes several dedicated studies designed to characterize its pharmacokinetic profile and prepare for global commercialization.[2]

• Clinical PK Studies: The design of ongoing PK studies reveals a mature and strategic approach to late-stage development. These studies are not merely for dose-finding but are focused on refining the product for market access and patient convenience.
• NCT06293365: This Phase 2, two-period crossover study is a critical "bridging" study. Its purpose is to demonstrate the pharmacokinetic comparability, or bioequivalence, between different product presentations. Specifically, it compares the exposure from a single 300 mg/2 mL auto-injector (AI) versus two separate 150 mg/1 mL pre-filled syringe (PFS) injections.[20] Establishing this equivalence is a necessary regulatory step to gain approval for the more patient-friendly auto-injector, which is likely the intended commercial delivery device for at-home administration.
• NCT06411639: This is an open-label, single-arm study designed specifically to characterize the PK profile of subcutaneous Ianalumab in Chinese adult participants with SLE and/or Sjögren's Disease.[23] The execution of population-specific PK studies is often a requirement for regulatory agencies in certain regions, such as China's National Medical Products Administration (NMPA). Conducting this study in parallel with global Phase 3 trials is a strategic maneuver to streamline and accelerate a potential global launch, including in key Asian markets.
• PK Parameters: The primary pharmacokinetic parameters being systematically evaluated in these trials are the standard measures of drug exposure: Area Under the concentration-time Curve (AUC), maximum observed serum concentration (Cmax), time to reach maximum concentration (Tmax), and trough serum concentration (Ctrough).[23] These data will be used to build population PK models to understand dose-exposure-response relationships and inform final dosing recommendations.
• Immunogenicity: As with all protein-based therapies, there is a potential for patients to develop an immune response against the drug itself. The development of anti-ianalumab antibodies (also known as anti-drug antibodies, or ADAs) is being monitored in clinical trials to assess the immunogenicity of the molecule.[24] The "fully human" nature of the antibody, derived from the HuCAL library, is intended to minimize this risk.

The pharmacodynamic data presents a clear and coherent narrative, demonstrating that Ianalumab's mechanism of action leads to the expected biological effects (B-cell depletion), which in turn modulate the downstream drivers of disease (autoantibodies) and correlate with clinical response biomarkers (IFNGS). This strong linkage from mechanism to clinical outcome provides a high degree of confidence in the drug's therapeutic rationale.

Section 4: The Clinical Development Program: A Multi-Indication Investigation

Ianalumab is being evaluated in a broad and ambitious clinical development program spanning multiple autoimmune diseases. The program is strategically focused on conditions where B-cell pathophysiology is a central driver, with several indications having advanced into late-stage, pivotal trials. The breadth of this program reflects a high level of confidence in the drug's mechanism and its potential to address significant unmet medical needs across rheumatology and hematology.

Table 3: Master Summary of Key Ianalumab Clinical Trials

Indication	Trial Identifier	Trial Name/Acronym	Phase	Status	Purpose
Sjögren's Syndrome (SS)	NCT02962895	-	2	Completed	Treatment
	NCT05350072	NEPTUNUS-1	3	Active, Not Recruiting	Treatment
	NCT05349214	-	3	Active, Not Recruiting	Treatment
	EUCT# 2022-502966-26-01	NEPTUNUS Extension	3	Ongoing	Long-term Safety
Systemic Lupus Erythematosus (SLE)	NCT03656562	-	2	Active, Not Recruiting	Treatment
	NCT05639114	SIRIUS-SLE 1	3	Recruiting	Treatment
	NCT05624749	SIRIUS-SLE 2	3	Recruiting	Treatment
	NCT06133972	SIRIUS-SLE Extension	3	Recruiting	Long-term Safety
Primary Immune Thrombocytopenia (ITP)	NCT05885555	VAYHIT3	2	Completed Recruitment	Treatment
	NCT05653349	VAYHIT1	3	Recruiting	Treatment (1st Line)
	NCT05653219	VAYHIT2	3	Active	Treatment (2nd Line)
	NCT07039422	VAY RE-HIT	2	Not Yet Recruiting	Treatment (Re-treatment)
Warm Autoimmune Hemolytic Anemia (wAIHA)	NCT05648968	VAYHIA	3	Recruiting	Treatment
Diffuse Cutaneous Systemic Sclerosis (dcSSc)	NCT06470048	-	2	Recruiting	Treatment
Rheumatoid Arthritis (RA)	NCT06293365	-	2	Recruiting	Basic Science (PK)
Discontinued Indications	-	-	1/2	Terminated	Chronic Lymphocytic Leukemia, IPF, MS, Pemphigus Vulgaris

4.1. Sjögren's Syndrome (SS)

The investigation of Ianalumab in Sjögren's Syndrome represents a potential landmark in the management of this debilitating disease.

• Disease Context & Standard of Care (SoC): Primary Sjögren's Syndrome (SS) is a systemic autoimmune disease primarily characterized by lymphocytic infiltration of the exocrine glands, leading to severe sicca symptoms, including xerostomia (dry mouth) and xerophthalmia (dry eyes).[26] Beyond the sicca component, patients often suffer from debilitating fatigue, pain, and systemic manifestations affecting the joints, skin, lungs, and kidneys.[27] The disease significantly impairs quality of life and increases the risk of developing non-Hodgkin lymphoma.[27] Despite its prevalence and impact, there are currently no approved systemic, disease-modifying therapies for SS.[18] The current standard of care is largely supportive and symptomatic, relying on over-the-counter products like artificial tears, prescription secretagogues such as pilocarpine (Salagen) and cevimeline (Evoxac) to stimulate saliva, and off-label use of immunosuppressants like hydroxychloroquine (Plaquenil) for systemic features.[26] Critically, several large, randomized trials of other biologic agents, including the B-cell depleting antibody rituximab and the BAFF-ligand inhibitor belimumab, have failed to demonstrate convincing evidence of efficacy in SS, leaving a profound unmet medical need for an effective systemic treatment.[29]
• Clinical Trials & Results:
• Phase 2b Dose-Finding Study (NCT02962895): This pivotal trial was a randomized, double-blind, placebo-controlled study that enrolled 190 patients with moderate-to-severe SS.[13] Patients received monthly subcutaneous doses of Ianalumab (5 mg, 50 mg, or 300 mg) or placebo for 24 weeks. The primary outcome was the change in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), a validated measure of systemic disease activity.
• 24-Week Efficacy: The study successfully met its primary endpoint, demonstrating a statistically significant dose-response relationship for the reduction in ESSDAI score.[13] The most pronounced effect was observed in the 300 mg dose group, which showed a placebo-adjusted least-squares mean reduction in ESSDAI of -1.92 points.[13] This achievement is particularly noteworthy, as it is considered the first time a large, randomized trial in primary SS has met its primary endpoint.[31] The 300 mg dose also resulted in a statistically significant improvement in the Physician's Global Assessment and a numerical trend toward improvement in stimulated salivary flow, an objective measure of glandular function.[13]
• 52-Week Efficacy (Extension Phase): Patients who continued on the 300 mg dose for a total of 52 weeks demonstrated sustained and even enhanced efficacy. Further improvements were seen in ESSDAI, as well as in the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), and both patient and physician global assessments, indicating a durable and deepening response with longer treatment duration.[33]
• Phase 3 Program (NEPTUNUS): Based on the compelling Phase 2b results, Novartis has advanced Ianalumab into a robust Phase 3 program for SS. Two large, multicenter trials, NEPTUNUS-1 (NCT05350072) and another identified as NCT05349214, have been initiated to confirm the efficacy and safety of Ianalumab in patients with active SS.[35] These trials are currently active but no longer recruiting participants. A long-term extension study (NEPTUNUS extension, EUCT# 2022-502966-26-01) is also underway to gather crucial long-term safety and efficacy data.[38]

The success of Ianalumab in its Phase 2b trial, in a field marked by the failure of other biologics, represents a significant potential breakthrough. It provides strong validation for its dual-action mechanism in the specific context of SS pathophysiology and has revitalized the prospect of developing the first-ever approved systemic, disease-modifying therapy for this underserved patient population.

4.2. Systemic Lupus Erythematosus (SLE)

The development of Ianalumab in SLE aims to provide a highly effective, steroid-sparing therapeutic option for this complex and heterogeneous autoimmune disease.

• Disease Context & SoC: SLE is a chronic, multi-system autoimmune disease characterized by the production of autoantibodies against nuclear antigens, leading to widespread inflammation and potential damage to the skin, joints, kidneys, brain, and other organs.[39] The management of SLE is complex and tailored to the specific organ systems involved. Hydroxychloroquine is considered a cornerstone therapy for all patients due to its ability to reduce disease flares.[41] Corticosteroids are widely used to control inflammation during flares but are associated with significant long-term toxicity.[43] For patients with more significant disease activity or organ involvement, conventional immunosuppressants such as mycophenolate mofetil, azathioprine, and methotrexate are employed.[41] In recent years, the therapeutic landscape has expanded to include targeted biologic agents, such as belimumab (anti-BAFF) and anifrolumab (anti-type I interferon receptor), which are approved for non-renal lupus.[42] Despite these advances, a substantial unmet need remains for therapies that can induce durable remission and minimize the cumulative burden of corticosteroid exposure.
• Clinical Trials & Results:
• Phase 2 Study (NCT03656562): This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of subcutaneous Ianalumab 300 mg administered monthly in patients with moderate-to-severe SLE.[44]
• Efficacy: The trial successfully met its primary endpoint at week 28. The endpoint was a rigorous composite measure requiring patients to achieve both a Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response and meet corticosteroid responder criteria (tapering to a dose of ≤5 mg/day). A significantly higher proportion of patients in the Ianalumab group (44.1%) achieved this composite endpoint compared to the placebo group (9.1%).[45] This result is highly clinically meaningful, as it demonstrates not only an ability to control underlying disease activity but also a potent steroid-sparing effect. Further analysis showed that continued treatment in an open-label extension period for up to one year resulted in additional clinical and laboratory benefits, suggesting that longer exposure deepens the therapeutic response.[46]
• Phase 3 Program (SIRIUS-SLE): The positive Phase 2 findings have propelled Ianalumab into a large-scale global Phase 3 program. Two pivotal trials, SIRIUS-SLE 1 (NCT05639114) and SIRIUS-SLE 2 (NCT05624749), are currently recruiting participants.[49] These studies are designed to evaluate the efficacy, safety, and tolerability of Ianalumab administered on top of standard-of-care therapy. SIRIUS-SLE 1 is exploring both monthly and quarterly subcutaneous dosing regimens.[50] A long-term extension study, SIRIUS-SLE Extension (NCT06133972), is also actively recruiting to provide data on the durability and long-term safety of treatment.[52]

The strategic choice of a primary endpoint that combines disease activity control with steroid reduction in the SLE clinical program highlights a modern approach to drug development in this field. Success in the Phase 3 trials on this endpoint would establish a powerful value proposition for Ianalumab as a therapy that can effectively manage lupus while mitigating the significant long-term morbidities associated with chronic corticosteroid use.

4.3. Primary Immune Thrombocytopenia (ITP)

In ITP, Novartis is pursuing a comprehensive development strategy for Ianalumab, investigating its potential across the full spectrum of the disease from first-line to heavily refractory settings.

• Disease Context & SoC: ITP is an autoimmune bleeding disorder characterized by immune-mediated destruction of platelets and impaired platelet production, leading to thrombocytopenia and an increased risk of bleeding.[53] The goal of treatment is to raise the platelet count to a safe level to prevent clinically significant bleeding. First-line therapy typically consists of a course of corticosteroids.[53] For patients who do not have a sustained response or who relapse, second-line options include thrombopoietin receptor agonists (TPO-RAs) like eltrombopag and romiplostim, splenectomy, and the B-cell depleting antibody rituximab. While these therapies can be effective, many patients require chronic treatment, and there remains a significant unmet need for therapies that can induce durable, treatment-free remission.[53]
• Clinical Trials & Results:
• Phase 2 Study (VAYHIT3, NCT05885555): This open-label, single-arm study was designed to assess Ianalumab in a difficult-to-treat population of patients who had failed at least two prior lines of therapy, including a corticosteroid and a TPO-RA.[54]
• Interim Efficacy: Interim results from the first 10 patients who completed 25 weeks of treatment showed promising activity. Five of the 10 patients (50%) achieved a confirmed response, defined as a platelet count of ≥50 G/L on at least two consecutive occasions without rescue therapy.[54] The response was notably rapid, with a median time to confirmed response of just 1.2 months.[54] These results provided strong proof-of-concept for Ianalumab's efficacy even in a heavily pretreated population.
• Phase 3 Program: Novartis has launched a broad Phase 3 program to establish Ianalumab's role across different stages of ITP treatment.
• VAYHIT1 (NCT05653349): This trial is evaluating Ianalumab as an add-on therapy to first-line corticosteroids.[56] Success in this study could position Ianalumab as part of the initial treatment regimen for newly diagnosed patients, potentially increasing the rate of durable remission from the outset.
• VAYHIT2 (NCT05653219): This study is investigating Ianalumab in combination with the TPO-RA eltrombopag for patients who have had an insufficient response to first-line steroids.[59] This addresses a common clinical scenario in the second-line setting.
• Re-treatment Study (VAY RE-HIT, NCT07039422): A Phase 2 study is planned to evaluate the efficacy of re-treating patients with ITP (and wAIHA) who have previously benefited from Ianalumab but subsequently relapsed.[61] This study will address the chronic, relapsing nature of the disease and provide data on the viability of intermittent therapy.

This multi-pronged development strategy in ITP is notable. By conducting simultaneous trials in the first-line, second-line, and refractory settings, as well as planning for re-treatment, Novartis is building a comprehensive data package intended to support the use of Ianalumab across the entire patient journey. This approach aims to establish Ianalumab not as a niche product, but as a foundational therapy in the management of ITP.

4.4. Warm Autoimmune Hemolytic Anemia (wAIHA)

The investigation of Ianalumab in wAIHA is supported by a strong preclinical rationale and aims to provide a novel, durable treatment option for this serious hematologic disorder.

• Disease Context & SoC: wAIHA is the most common form of autoimmune hemolytic anemia, caused by IgG autoantibodies that bind to the surface of red blood cells (RBCs) at body temperature, leading to their premature destruction (hemolysis), primarily in the spleen.[63] The resulting anemia can cause fatigue, weakness, and, in severe cases, life-threatening complications.[64] The treatment paradigm for wAIHA mirrors that of ITP, with corticosteroids serving as the standard first-line therapy.[63] For patients who are refractory or become steroid-dependent, second-line options include rituximab and splenectomy.[63] As in ITP, there is a significant need for therapies that can induce lasting remission after a finite course of treatment.[53]
• Clinical Trials & Rationale:
• Preclinical Rationale: The rationale for using Ianalumab in wAIHA is supported by compelling preclinical data. In a mouse model of the disease, treatment with Ianalumab led to a significant reduction in circulating B-cells and, critically, a decrease in the levels of pathogenic anti-RBC autoantibodies.[67] Beyond its effect on B-cells, the study revealed a deeper immunomodulatory impact: Ianalumab treatment corrected the imbalance between pathogenic effector T-cells (Teff) and protective regulatory T-cells (Treg) in the spleen.[67] In autoimmunity, this ratio is often skewed toward a pro-inflammatory Teff phenotype. The ability of Ianalumab to help restore this balance toward a more tolerant state suggests a potential to "reset" the immune system, providing a strong biological basis for achieving durable, treatment-free responses.
• Phase 3 Study (VAYHIA, NCT05648968): Based on this rationale, Novartis has initiated a pivotal Phase 3, randomized, double-blind, placebo-controlled trial named VAYHIA.[68] The study is actively recruiting patients with wAIHA who have failed at least one prior line of therapy. The primary objective is to demonstrate that Ianalumab can induce a durable hemoglobin response, defined as achieving a hemoglobin level of ≥10 g/dL with an increase of ≥2 g/dL from baseline for at least 8 consecutive weeks.[68] A key secondary objective is to assess the duration of this response after treatment has been completed, directly testing the hypothesis that Ianalumab can induce lasting remission.[68]

4.5. Other Investigational Programs

Beyond its four lead indications, Novartis is exploring the potential of Ianalumab in other autoimmune conditions while also strategically discontinuing programs in other areas.

• Active Programs:
• Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Phase 2, randomized, placebo-controlled trial (NCT06470048) is currently recruiting approximately 200 participants to evaluate the efficacy and safety of Ianalumab in dcSSc, a severe autoimmune disease characterized by widespread skin and organ fibrosis.[71]
• Rheumatoid Arthritis (RA): Ianalumab is being investigated in RA, with a Phase 2 trial actively recruiting participants.[72] A Phase 1 study in this indication has been completed.[2]
• Discontinued Programs: Clinical development of Ianalumab has been discontinued for several indications, including Chronic Lymphocytic Leukemia (CLL), Idiopathic Pulmonary Fibrosis (IPF), Multiple Sclerosis (MS), and Pemphigus Vulgaris (PV).[2] Additionally, a Phase 1 trial in Non-Hodgkin's Lymphoma was terminated due to a business decision, not due to any safety or tolerability concerns.[6]

The pattern of advancing versus discontinued programs reveals a clear and deliberate corporate strategy. Novartis is concentrating its significant resources on a core set of systemic autoimmune diseases where B-cell hyperactivity and autoantibody production are the undisputed central pathogenic mechanisms (SS, SLE, ITP, wAIHA, dcSSc). Indications where the pathophysiology is more heterogeneous or T-cell-driven (MS), primarily fibrotic (IPF), or where the oncology market is highly competitive and requires a different development path (CLL, NHL) have been strategically deprioritized. This focused approach maximizes the probability of success by aligning the asset's potent B-cell-modulating mechanism with the diseases it is most likely to impact profoundly.

Section 5: Integrated Safety and Tolerability Profile

The safety and tolerability of an investigational therapy are paramount to its potential clinical utility and regulatory success. An integrated analysis of safety data from across the Ianalumab clinical development program provides a comprehensive overview of its risk profile.

5.1. Comprehensive Safety Analysis

Data consolidated from completed Phase 1 and Phase 2 studies in Sjögren's Syndrome (SS), Systemic Lupus Erythematosus (SLE), and Chronic Lymphocytic Leukemia (CLL) indicate that Ianalumab possesses a favorable and manageable safety profile.[53] This conclusion is supported by longer-term data from the SLE program, where treatment for up to one year was found to be well tolerated.[48]

Across these studies, the majority of reported adverse events (AEs) have been mild or moderate in severity.[53] In the large Phase 2b trial in SS, the overall incidence of treatment-emergent AEs was comparable between the Ianalumab dose groups and the placebo group, suggesting that the drug does not lead to a broad increase in general adverse events.[13] In the more heavily pretreated ITP population from the VAYHIT3 trial, AEs were common, with 82% of patients experiencing at least one event; however, Grade ≥3 AEs were less frequent (26%), and no discontinuations due to AEs occurred.[54]

5.2. Adverse Events of Special Interest

Specific AEs are monitored closely with any B-cell modulating therapy. For Ianalumab, the profile is as follows:

• Injection-Site Reactions (ISRs): Consistent with a subcutaneously administered biologic, ISRs are among the most frequently reported AEs. In the SS trial, ISRs were mostly mild and demonstrated a dose-response relationship, being more common at higher doses.[13]
• Infections: A critical concern for any potent immunomodulatory agent is the risk of infection. The data for Ianalumab to date are highly encouraging in this regard. In the placebo-controlled SS trial, the frequency of infections and infestations was similar between patients treated with Ianalumab and those receiving placebo.[53] Similarly, in the blinded period of the SLE trial, no serious infections were reported in the Ianalumab arm.[53] While infections were reported in 33% of patients in the VAYHIT3 ITP trial, only one was Grade ≥3, and this was in a heavily pretreated population.[54] This overall low risk of serious infection, if maintained in Phase 3 data, could represent a significant competitive advantage over other immunosuppressants that carry a greater infectious risk.
• Neutropenia: A decrease in neutrophil count has been identified as an AE associated with Ianalumab. It was the most common Grade ≥3 AE observed in the Phase 1b trial in CLL.[53] Cases of Grade 3 neutropenia were also observed during the post-treatment follow-up period of the SS trial; however, these instances were transient and notably were not associated with clinical infections.[33]
• Hypogammaglobulinemia: Long-term B-cell depletion can lead to a reduction in total immunoglobulin levels, which can increase infection risk. However, the integrated safety summary across the Ianalumab program reported no cases of clinically significant hypogammaglobulinemia.[53] While a reduction in total IgG levels from baseline was observed in the SLE trial, this is an expected pharmacodynamic consequence of B-cell depletion and did not appear to translate into adverse clinical outcomes.[46]
• Serious Adverse Events (SAEs): The rate of SAEs has generally been low across the program. In the SLE trial, only one SAE (renal impairment) was reported during the blinded period, and no SAEs in the subsequent open-label period were considered related to the study drug.[45] In the SS trial, three ianalumab-treated patients experienced SAEs, with two events in a single patient (appendicitis and tubo-ovarian abscess) being considered possibly related to treatment.[53]

The overall safety profile emerging from the extensive clinical evaluation of Ianalumab is promising. The benefit-risk assessment appears favorable, particularly given the encouragingly low signal for serious infections in placebo-controlled settings. This suggests that the specific dual mechanism of Ianalumab may achieve potent therapeutic efficacy without inducing the level of broad immune suppression that often leads to significant infectious complications with other agents.

Section 6: Regulatory and Strategic Landscape

The progression of an investigational drug through regulatory pathways provides critical insight into its development maturity and commercial trajectory. Ianalumab's interactions with major global health authorities demonstrate a clear, well-funded, and strategic path toward market authorization for its lead indications.

6.1. Current Regulatory Status

As an investigational compound, Ianalumab has not yet received marketing approval from any regulatory agency worldwide.

• United States (Food and Drug Administration - FDA): Ianalumab remains an unapproved, investigational drug in the United States.[73] Novartis has established expanded access programs, which can allow patients with serious diseases who are unable to participate in clinical trials to receive the investigational treatment under specific circumstances.[75]
• European Union (European Medicines Agency - EMA): Similarly, Ianalumab is not authorized for marketing in the European Community.[76] However, it is under extensive clinical investigation across numerous member states, with multiple trials registered in the EU Clinical Trials Register, signifying a robust European development program.[38]

6.2. Key Regulatory Milestones

Despite its investigational status, Ianalumab has achieved several important regulatory milestones that signal its advanced stage of development and Novartis's commitment to its commercialization. These milestones are complex, resource-intensive processes that are typically pursued only for high-priority assets with a strong likelihood of success.

• FDA Orphan Drug Designation: On February 13, 2025, the U.S. FDA granted Orphan Drug Designation to Ianalumab for the treatment of primary immune thrombocytopenia (ITP).[73] This designation is granted to therapies for rare diseases (affecting fewer than 200,000 people in the U.S.) and provides significant development incentives, including potential market exclusivity for seven years post-approval, tax credits for clinical research, and a waiver of prescription drug user fees. This milestone enhances the commercial viability of the ITP indication.
• EMA Paediatric Investigation Plans (PIPs): Securing an agreement on a PIP with the EMA's Paediatric Committee (PDCO) is a mandatory prerequisite for submitting a Marketing Authorisation Application (MAA) for any new medicine in Europe. Novartis has proactively and successfully navigated this process for multiple Ianalumab indications.
• For Immune Thrombocytopenia (ITP): A PIP was formally agreed upon on June 14, 2024 (EMEA-002338-PIP05-23). The plan outlines the required pediatric studies, which will include an open-label trial in patients aged 5 to less than 18 years. It also grants a waiver for the youngest pediatric population (birth to less than 5 years), on the grounds that the drug is not expected to provide a significant therapeutic benefit in this age group.[76]
• For Warm Autoimmune Hemolytic Anemia (wAIHA): A PIP for the wAIHA indication was agreed upon on March 8, 2024 (EMEA-002338-PIP04-23), which also includes a deferral (allowing pediatric studies to be conducted after the initial adult approval) and a waiver for certain pediatric subsets.[78]

The successful negotiation of these complex regulatory requirements in both the U.S. and Europe is a strong indicator of a mature, pre-commercial asset. It demonstrates that Novartis has presented a robust and acceptable long-term development strategy to global regulators and is methodically executing the necessary steps to support future marketing applications. This shifts the perception of Ianalumab from a purely investigational compound to an asset on a defined and de-risked trajectory to market.

Section 7: Concluding Analysis and Future Outlook

7.1. Synthesis of Evidence

Ianalumab (VAY736) has emerged from an extensive clinical development program as a highly promising therapeutic candidate for a range of B-cell-mediated autoimmune diseases. The strength of the evidence supporting its potential is built upon a foundation of rational drug design. Its dual mechanism of action—combining potent, ADCC-mediated B-cell depletion with a simultaneous blockade of the critical BAFF-R survival pathway—is scientifically compelling and appears to be a key differentiator from previous generations of B-cell therapies.

This sophisticated mechanism translates into profound and consistent pharmacodynamic effects, characterized by rapid, deep, and sustained depletion of multiple B-cell subsets and a corresponding reduction in pathogenic autoantibodies. Crucially, the clinical data generated to date, particularly from randomized, controlled Phase 2 trials, suggest that these biological effects lead to clinically meaningful improvements for patients. The landmark success in Sjögren's Syndrome, the robust steroid-sparing efficacy in SLE, and the rapid responses in refractory ITP collectively form a compelling body of evidence that validates the therapeutic hypothesis. This is further bolstered by a safety profile that, thus far, appears manageable and potentially advantageous, particularly with respect to the risk of serious infection.

7.2. Unmet Needs and Therapeutic Potential

Should the ongoing Phase 3 trials confirm the positive results seen in Phase 2, Ianalumab has the potential to significantly alter the treatment landscape for several challenging diseases and address major unmet medical needs.

• For Sjögren's Syndrome, Ianalumab is on a trajectory to become the first-ever approved systemic, disease-modifying therapy. This would represent a paradigm shift for a patient population that has long been managed with only symptomatic and off-label treatments.
• For Systemic Lupus Erythematosus, its demonstrated ability to control disease activity while enabling significant corticosteroid reduction positions it as a potent steroid-sparing option. This could help mitigate the substantial long-term morbidity associated with chronic steroid use, a primary goal of modern lupus management.
• For ITP and wAIHA, the potential of Ianalumab to induce durable, treatment-free remission could transform the therapeutic goal from chronic disease management to achieving a long-term cure or operational cure for a subset of patients. This would be a major advance over current therapies, which often require continuous administration to maintain a response.

7.3. Future Challenges and Research Directions

The primary challenge for Ianalumab is to translate its strong Phase 2 promise into unequivocal Phase 3 victories across its lead indications. The successful execution and positive readout of the large, global SIRIUS, NEPTUNUS, VAYHIT, and VAYHIA trials are the final hurdles to regulatory approval.

Looking forward, future research should focus on several key areas to optimize the clinical use of Ianalumab. A critical direction will be the validation of biomarkers to predict therapeutic response. The early signal linking a decrease in the interferon gene signature to clinical response in SLE warrants further investigation and could pave the way for a more personalized medicine approach, allowing for the selection of patients most likely to benefit.

Further research will also be needed to define the optimal duration of therapy. The preclinical data suggesting a potential for immune system "reset" raises the exciting possibility that a finite course of treatment could induce long-term remission. The long-term extension studies and the planned re-treatment trial in ITP will be crucial for understanding the durability of response and establishing protocols for maintenance or intermittent therapy. Finally, continued long-term safety surveillance will be essential to fully characterize the risk profile of profound B-cell suppression over many years.

In conclusion, Ianalumab stands as a testament to rational, mechanism-based drug design. With a differentiated dual mechanism of action, compelling mid-stage clinical data, and a strategic, well-executed late-stage development program, it is firmly positioned as one of the most significant pipeline assets in autoimmunity, holding the potential to become a transformative therapy for patients with Sjögren's Syndrome, SLE, ITP, and wAIHA.

Works cited

1. Ianalumab - Wikipedia, accessed August 5, 2025, https://en.wikipedia.org/wiki/Ianalumab
2. Ianalumab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/drugs/DB16666
3. Ianalumab | TargetMol, accessed August 5, 2025, https://www.targetmol.com/compound/ianalumab
4. CAS 1929549-92-7 Ianalumab - BOC Sciences, accessed August 5, 2025, https://www.bocsci.com/product/ianalumab-cas-1929549-92-7-460424.html
5. Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) CD markers antibody - Selleckchem.com, accessed August 5, 2025, https://www.selleckchem.com/products/ianalumab-anti-tnfrsf13c-baffr-cd268.html
6. Ianalumab - MorphoSys/Novartis - AdisInsight - Springer, accessed August 5, 2025, https://adisinsight.springer.com/drugs/800037006
7. Ianalumab (VAY-736) | Anti-BAFF-R - MedchemExpress.com, accessed August 5, 2025, https://www.medchemexpress.com/ianalumab.html
8. 95. Autoimmune hepatitis Clinical trials / Disease details - DDrare, accessed August 5, 2025, https://ddrare.nibn.go.jp/ddrare_Mar2023/cgi-bin/disease_who_e.cgi?id=95&query=%22Ianalumab%22
9. ianalumab | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 5, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=immuno&ligandId=10656
10. Ianalumab (VAY-736) | CAS 1929549-92-7 - AbMole BioScience, accessed August 5, 2025, https://www.abmole.com/products/ianalumab.html
11. ianalumab | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 5, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=10656
12. IANALUMAB'S DUAL MODE OF ACTION: TARGETING B CELLS ..., accessed August 5, 2025, https://www.jrheum.org/content/52/Suppl_1/244.1
13. op0302 ianalumab (vay736), a dual mode of action biologic combining baff receptor inhibition with b cell depletion, reaches primary endpoint for treatment of primary sjogren's syndrome - ResearchGate, accessed August 5, 2025, https://www.researchgate.net/publication/348777559_OP0302_IANALUMAB_VAY736_A_DUAL_MODE_OF_ACTION_BIOLOGIC_COMBINING_BAFF_RECEPTOR_INHIBITION_WITH_B_CELL_DEPLETION_REACHES_PRIMARY_ENDPOINT_FOR_TREATMENT_OF_PRIMARY_SJOGREN'S_SYNDROME
14. www.assaygenie.com, accessed August 5, 2025, https://www.assaygenie.com/blog/ianalumab-exploring-its-mechanism-clinical-applications-and-research-potential/#:~:text=What%20is%20the%20mechanism%20of,cells%20responsible%20for%20autoimmune%20damage.
15. Ianalumab: Exploring Its Mechanism, Clinical Applications, and Research Potential, accessed August 5, 2025, https://www.assaygenie.com/blog/ianalumab-exploring-its-mechanism-clinical-applications-and-research-potential/
16. What is Ianalumab used for? - Patsnap Synapse, accessed August 5, 2025, https://synapse.patsnap.com/article/what-is-ianalumab-used-for
17. (PDF) Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity - ResearchGate, accessed August 5, 2025, https://www.researchgate.net/publication/331475043_Treatment_of_primary_Sjogren's_syndrome_with_ianalumab_VAY736_targeting_B_cells_by_BAFF_receptor_blockade_coupled_with_enhanced_antibody-dependent_cellular_cytotoxicity
18. OP0302 IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF PRIMARY SJOGREN'S SYNDROME | Annals of the Rheumatic Diseases, accessed August 5, 2025, https://ard.bmj.com/content/79/Suppl_1/187.1
19. POS0540 REDUCTION OF B CELL SUBSETS, AUTOANTIBODIES AND DISEASE-RELEVANT PATHWAYS IN IANALUMAB TREATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: FINDINGS FROM A PHASE 2 CLINICAL TRIAL, accessed August 5, 2025, https://ard.bmj.com/content/83/Suppl_1/956
20. Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | Clinical Research Trial Listing - CenterWatch, accessed August 5, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06293365/two-period-crossover-study-to-demonstrate-the-comparability-of-pharmacokinetics-of-subcutaneous-ianalumab-between-2ml-auto-injector-2ml-pfs-with1ml-pre-filled-syringe-in-adult-participants-with-autoimmune-disease
21. Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | ClinicalTrials.gov, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT06293365?cond=lupus&term=Ianalumab&rank=6
22. Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | Novartis, accessed August 5, 2025, https://www.novartis.com/clinicaltrials/study/nct06293365
23. Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT06411639?cond=lupus&term=Ianalumab&rank=2
24. Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT06411639
25. Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases, accessed August 5, 2025, https://ctv.veeva.com/study/pharmacokinetics-study-of-ianalumab-in-chinese-participants-with-autoimmune-diseases
26. Sjogren's syndrome - Diagnosis and treatment - Mayo Clinic, accessed August 5, 2025, https://www.mayoclinic.org/diseases-conditions/sjogrens-syndrome/diagnosis-treatment/drc-20353221
27. Diagnosing Sjogren's Syndrome - NYU Langone Health, accessed August 5, 2025, https://nyulangone.org/conditions/sjogrens-syndrome/diagnosis
28. Treatment | Sjögren's Foundation, accessed August 5, 2025, https://sjogrens.org/understanding-sjogrens/treatment
29. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome - Pure, accessed August 5, 2025, https://pure-oai.bham.ac.uk/ws/files/151261015/VAY_Manuscript_revised_Final_03Sep2021_clean.pdf
30. Diagnosis and Management of Sjögren Syndrome - AAFP, accessed August 5, 2025, https://www.aafp.org/pubs/afp/issues/2009/0315/p465.html
31. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/34861168/
32. #VisualAbstract: Ianalumab shows a dose-related improvement in disease activity in Sjögren's syndrome without serious adverse events | 2 Minute Medicine, accessed August 5, 2025, https://www.2minutemedicine.com/visualabstract-ianalumab-shows-a-dose-related-improvement-in-disease-activity-in-sjogrens-syndrome-without-serious-adverse-events/
33. Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/39557617/
34. Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study - Johns Hopkins University, accessed August 5, 2025, https://pure.johnshopkins.edu/en/publications/safety-and-efficacy-of-ianalumab-in-patients-with-sj%C3%B6grens-diseas
35. Ianalumab Active Not Recruiting Phase 3 Trials for Sjögren's Syndrome (SS) Treatment, accessed August 5, 2025, https://go.drugbank.com/drugs/DB16666/clinical_trials?conditions=DBCOND0163993&phase=3&purpose=treatment&status=active_not_recruiting
36. Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) - ClinicalTrials.gov, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT05349214
37. Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) - ClinicalTrials.gov, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT05350072
38. Clinical Trials in the European Union - EMA, accessed August 5, 2025, https://euclinicaltrials.eu/ctis-public/view/2022-502966-26-01
39. Systemic lupus erythematosus: MedlinePlus Medical Encyclopedia, accessed August 5, 2025, https://medlineplus.gov/ency/article/000435.htm
40. Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management, accessed August 5, 2025, https://www.aafp.org/pubs/afp/issues/2016/0815/p284.html
41. Systemic Lupus Erythematosus - StatPearls - NCBI Bookshelf, accessed August 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK535405/
42. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update | Annals of the Rheumatic Diseases, accessed August 5, 2025, https://ard.bmj.com/content/83/1/15
43. Lupus - Diagnosis & treatment - Mayo Clinic, accessed August 5, 2025, https://www.mayoclinic.org/diseases-conditions/lupus/diagnosis-treatment/drc-20365790
44. Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients - ClinicalTrials.gov, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT03656562
45. Ianalumab in patients with systemic lupus erythematosus: Interim results of a phase II trial, accessed August 5, 2025, https://lupushub.com/medical-information/ianalumab-in-patients-with-systemic-lupus-erythematosus-interim-results-of-a-phase-ii-trial
46. OP0089 PHASE 2 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED EVERY 4 WEEKS UP TO 48 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - ResearchGate, accessed August 5, 2025, https://www.researchgate.net/publication/382807901_OP0089_PHASE_2_SAFETY_AND_EFFICACY_OF_SUBCUTANEOUS_SC_DOSE_IANALUMAB_VAY736_ANTI-BAFFR_mAb_ADMINISTERED_EVERY_4_WEEKS_UP_TO_48_WEEKS_IN_PATIENTS_WITH_SYSTEMIC_LUPUS_ERYTHEMATOSUS_SLE
47. POS0120 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Annals of the Rheumatic Diseases, accessed August 5, 2025, https://ard.bmj.com/content/82/Suppl_1/275.2
48. OP0089 PHASE 2 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED EVERY 4 WEEKS UP TO 48 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Annals of the Rheumatic Diseases, accessed August 5, 2025, https://ard.bmj.com/content/83/Suppl_1/140.2
49. Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care ..., accessed August 5, 2025, https://www.novartis.com/clinicaltrials/study/nct05624749
50. Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | ClinicalTrials.gov, accessed August 5, 2025, https://www.clinicaltrials.gov/study/NCT05639114
51. Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | Novartis, accessed August 5, 2025, https://www.novartis.com/clinicaltrials/study/nct05639114
52. Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | Novartis, accessed August 5, 2025, https://www.novartis.com/clinicaltrials/study/nct06133972
53. Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic, accessed August 5, 2025, https://ashpublications.org/blood/article/142/Supplement%201/5427/499591/Ianalumab-a-Novel-Anti-B-Cell-Activating-Factor
54. A PHASE 2 STUDY OF IANALUMAB IN PATIENTS WITH PRIMARY IMMUNE... - Bradbury C - EHA-2084 - Jun 15 2025, accessed August 5, 2025, https://library.ehaweb.org/eha/2025/eha2025-congress/4159389/charlotte.bradbury.a.phase.2.study.of.ianalumab.in.patients.with.primary.html?f=
55. Phase II VAYHIT3 Interim Results: Primary Immune Thrombocytopenia - CCO, accessed August 5, 2025, https://clinicaloptions.com/activities/download/57826/slug/vayhit3-trial-of-ianalumab/67826
56. Clinical Trials Using Ianalumab - NCI, accessed August 5, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/ianalumab?pn=1
57. Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) | Novartis, accessed August 5, 2025, https://www.novartis.com/clinicaltrials/study/nct05653349
58. Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1) - ClinicalTrials.gov, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT05653349
59. A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition toeltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response orrelapsed after first line steroid treatment (VAYHIT2 - Experts@Minnesota, accessed August 5, 2025, https://experts.umn.edu/en/projects/a-phase-3-randomized-double-blind-study-of-ianalumab-vay736-versu
60. EU Clinical Trials Register, accessed August 5, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001627-32/NL
61. Ianalumab Not Yet Recruiting Phase 2 Trials for Primary Immune Thrombocytopenia (ITP) Treatment - DrugBank, accessed August 5, 2025, https://go.drugbank.com/drugs/DB16666/clinical_trials?conditions=DBCOND0107274&phase=2&purpose=treatment&status=not_yet_recruiting
62. Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab | ClinicalTrials.gov, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT07039422
63. Autoimmune Hemolytic Anemia - Hematology and Oncology - Merck Manuals, accessed August 5, 2025, https://www.merckmanuals.com/professional/hematology-and-oncology/anemias-caused-by-hemolysis/autoimmune-hemolytic-anemia
64. Warm Autoimmune Hemolytic Anemia - Symptoms, Causes, Treatment | NORD, accessed August 5, 2025, https://rarediseases.org/rare-diseases/warm-autoimmune-hemolytic-anemia/
65. Autoimmune Hemolytic Anemia: Treatment, Symptoms & Types - Cleveland Clinic, accessed August 5, 2025, https://my.clevelandclinic.org/health/diseases/22349-autoimmune-hemolytic-anemia
66. Treatment of autoimmune hemolytic anemias - PMC, accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4181250/
67. EFFICACY OF IANALUMAB IN A MOUSE MODEL OF AUTOIMMUNE HEMOLYTIC... - Yazdanbakhsh K - EHA-2494 - Jun 14 2025, accessed August 5, 2025, https://library.ehaweb.org/eha/2025/eha2025-congress/4161331/karina.yazdanbakhsh.efficacy.of.ianalumab.in.a.mouse.model.of.autoimmune.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Aspeaker%3D668009%2Asearch%3Danemia
68. A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia | Novartis, accessed August 5, 2025, https://www.novartis.com/clinicaltrials/study/nct05648968
69. A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia | Novartis, accessed August 5, 2025, https://uat2.arctic.novartis.com/clinicaltrials/study/nct05648968
70. PB2552: VAYHIA: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IANALUMAB VS PLACEBO IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA THAT FAILED ≥1 LINE OF TREATMENT - PMC, accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10428764/
71. A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | Novartis, accessed August 5, 2025, https://www.novartis.com/clinicaltrials/study/nct06470048
72. Rheumatoid Arthritis Recruiting Phase 2 Trials for Ianalumab (DB16666) | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/indications/DBCOND0027961/clinical_trials/DB16666?phase=2&status=recruiting
73. Search Orphan Drug Designations and Approvals - accessdata.fda ..., accessed August 5, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1018924
74. A Study of Experimental Medicine VAY736 For Autoimmune Hepatitis - Studypages, accessed August 5, 2025, https://studypages.com/s/a-study-of-experimental-medicine-vay736-for-autoimmune-hepatitis-283699/
75. Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | ClinicalTrials.gov, accessed August 5, 2025, https://www.clinicaltrials.gov/study/NCT05624749
76. European Medicines Agency decision P/0198/2024 of 14 June 2024 ..., accessed August 5, 2025, https://www.ema.europa.eu/en/documents/pip-decision/p-0198-2024-ema-decision-14-june-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-ianalumab-emea-002338-pip05-23_en.pdf
77. PT - EU Clinical Trials Register, accessed August 5, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002691-36/PT
78. EMEA-002338-PIP04-23 - paediatric investigation plan - EMA - European Union, accessed August 5, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002338-pip04-23